CorporateR&D Collaboration
Almirall and Proteros Biostructures announce successful achievement of key scientific milestone in structural biology collaboration
Almirall and Proteros Biostructures announce successful achievement of key scientific milestone in structural biology collaboration
By: Almirall
23/07/2008
Barcelona, 23 July 2008.-Laboratorios Almirall S.A. and Proteros biostructures GmbH announced that they have achieved a scientific milestone in their collaboration –in force since mid 2006- to solve structures of a prominent Almirall drug discovery target in combination with proprietary Almirall compounds triggering commercial payments to Proteros.
Proteros applied its industrial structural biology platform and proprietary technologies to deliver protein ligand structures to Almirall Scientists for a known, extremely challenging protein where little published data is available, particularly on solving specific protein ligand structures. Proteros delivered the solved structures within the timeframes agreed at the beginning of the collaboration.
Almirall’s Executive Director for the R&D Area, Dr Per Olof Andersson said: “the relationship with Proteros is an excellent example of Almirall’s strategy of accessing cutting edge science by collaborating with leading external providers to compliment our internal resources and ultimately accelerate our drug discovery programmes.”
Commenting on this achievement, Proteros Chief Executive Officer, Dr Torsten Neuefeind said: “we are pleased that Proteros’ approach to structural biology, of applying our unique technologies in an industrial process, has proven to offer an effective and valuable service to our client’s scientists allowing them to make early decision on their drug discovery programmes. We look forward to delivering similar valuable structural information on our current and future collaborations with Almirall”.
Almirall
Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis.Almirall’s medicines are currently present in over 70 countries with direct presence in Europe and Latin America in 11 countries. For further information please visit the website at: www.almirall.com
Proteros Biostructures GmbH
Proteros biostructures provides services and unique technologies for X-ray protein structure analysis and fragment screening to the life science industries. The company accelerates and improves structure analysis and structure-based drug discovery by its expertise, industrialised process and unique technologies, e.g. Free Mounting SystemTM and PicodropperTM, enabling cost-efficient protein-ligand-structure analyses and compound kinetic profiling. Proteros complements its clients’ internal capabilities with its external expertise and access to flexible resources. Proteros currently provides services to over fifty pharmaceutical and biotechnology companies in North America, Europe and Japan. More information about Proteros can be found on the company’s website atwww.proteros.com
Para más información:
Ketchum/SEIS
Sonia San Segundo
Tel.: 91 788 32 00
Press release